Landos Biopharma's Groundbreaking NX-13 Provides Hope for Ulcerative Colitis Patients
In the world of medical advancements, Landos Biopharma Inc. has emerged as a noteworthy player with its lead asset, NX-13 – a first-in-class oral NLRX1 agonist currently in Phase 2 for the treatment of ulcerative coliti...
Mar 25, 2024
• Major Pharmaceutical Preparations Industry
Merger and Acquisition
